β受体阻滞剂与心衰维持性透析患者死亡风险的关系
该回顾性队列研究纳入3503例合并心衰的慢性肾脏病成人患者,在2007年至2016年间开始维持性透析时评估β受体阻滞剂使用情况。结果显示,使用β受体阻滞剂与6个月内全因死亡率降低相关(HR 0.79,95%CI 0.65-0.94),美托洛尔使用者HR为0.68(95%CI 0.53-0.88),但住院风险未见差异。
要点
- 心衰患者启动透析时使用β受体阻滞剂与6个月内全因死亡率降低相关。
- 使用美托洛尔者6个月内全因死亡率降低更明显(HR 0.68)。
- β受体阻滞剂使用与6个月内全因或心血管相关住院无显著差异。
核心结论
- 在合并心衰的维持性透析患者中,β受体阻滞剂使用与6个月内全因死亡率降低相关,但未观察到住院风险的差异。
研究设计与样本
- 回顾性队列研究,纳入2007年1月1日至2016年6月30日期间在整合医疗系统内启动血液透析或腹膜透析的3503例合并心衰的慢性肾脏病成人患者。
主要发现
- 3503例患者中,2115例(60.4%)在透析转换时使用β受体阻滞剂。
- 与未使用者相比,任何β受体阻滞剂使用者6个月内全因死亡HR为0.79(95%CI 0.65-0.94)。
- 美托洛尔使用者在透析转换时6个月内全因死亡HR为0.68(95%CI 0.53-0.88)。
- 全因住院或心血管相关住院方面未观察到差异。
临床怎么用
- 对于合并心衰并准备启动维持性透析的患者,可考虑使用β受体阻滞剂以降低早期死亡风险。
局限性
- 观察性研究设计无法完全控制残余混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONAL & OBJECTIVE: Beta-blockers are recommended for patients with heart failure (HF) but their benefit in the dialysis population is uncertain. Beta-blockers are heterogeneous, including with respect to their removal by hemodialysis. We sought to evaluate whether β-blocker use and their dialyzability characteristics were associated with early mortality among patients with chronic kidney disease with HF who transitioned to dialysis. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Adults patients with chronic kidney disease (aged≥18 years) and HF who initiated either hemodialysis or peritoneal dialysis during January 1, 2007, to June 30, 2016, within an integrated health system were included. EXPOSURES: Patients were considered treated with β-blockers if they had a quantity of drug dispensed covering the dialysis transition date. OUTCOMES: All-cause mortality within 6 months and 1 year or hospitalization within 6 months after transition to maintenance dialysis. ANALYTICAL APPROACH: Inverse probability of treatment weights using propensity scores was used to balance covariates between treatment groups. Cox proportional hazard analysis and logistic regression were used to investigate the association between β-blocker use and study outcomes. RESULTS: 3,503 patients were included in the study. There were 2,115 (60.4%) patients using β-blockers at transition. Compared with nonusers, the HR for all-cause mortality within 6 months was 0.79 (95% CI, 0.65-0.94) among users of any β-blocker and 0.68 (95% CI, 0.53-0.88) among users of metoprolol at transition. There were no observed differences in all-cause or cardiovascular-related hospitalization. LIMITATIONS: The observational nature of our study could not fully account for residual confounding. CONCLUSIONS: Beta-blockers were associated with a lower rate of mortality among incident hemodialysis patients with HF. Similar associations were not observed for hospitalizations within the first 6 months following transition to dialysis.
引用
- Zhou H, Sim JJ, Shi J, et al. β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis. Am J Kidney Dis. 2020. PMID: 33010357. doi:10.1053/j.ajkd.2020.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。